Sollinger 2001.

Methods	Open‐label RCT
Participants	Setting: National multi centre (6) Country: USA Cadaveric (62%), first (81%) kidney transplant Mean age (± SD) Group 1: 44.5 ± 13.7 Group 2: 49.8 ± 11.9 Number (group 1/group 2):138 (70/68) Sex (M/F) Group 1: 37/33 Group 2: 42/23 Exclusions: Human leukocyte antigen (HLA)‐identical donor; third or subsequent transplant; previously transplanted with another organ other than kidney; multiple organ transplants
Interventions	Treatment group 1 Basiliximab: 20 mg days 0 and 4 Treatment Group 2 ATG (ATGAM): 15 mg/kg/d with 48 hrs for up to 14 days Baseline immunosuppression CSA: Initial dose 3‐5 mg/kg and dose then adjusted to therapeutic trough (NS) MMF: 2‐3 g/d for minimum of 12 months Steroids: 0.5‐1.0 g day 1 then tapered to 20 mg/d by day 28 and then maintained between 5‐15 mg/d
Outcomes	Mortality Graft loss Acute rejection Infection/CMV Delayed graft function Adverse reaction Malignancy
Notes	1 year follow‐up
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated "randomised", no further information provided
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) Objective outcomes	High risk	Open label, blinding of outcome assessors not stated
Blinding (performance bias and detection bias) Subjective outcomes	High risk	Open label, blinding of outcome assessors not stated
Incomplete outcome data (attrition bias) All outcomes	High risk	Not ITT. Six patients excluded: 3 did not receive treatment, 2 withdrew consent and 1 lost to follow‐up ‐ all for ATG group
Selective reporting (reporting bias)	Low risk	Primary outcomes for this review (death, graft loss and acute rejection) have been reported
Other bias	High risk	"Supported by Novartis Pharmaceuticals", one author an employee of Novartis